Goldman Sachs’s Oncolytics Biotech ONCY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$125K Buy
186,639
+16,741
+10% +$13.6K ﹤0.01% 6309
2026
Q2
$161K Buy
+169,898
New +$158K ﹤0.01% 6252
2026
Q1
– Sell
-169,899
Closed -$148K – 6851
2025
Q4
$148K Sell
169,899
-38,799
-19% -$41.9K ﹤0.01% 6116
2025
Q3
$292K Buy
208,698
+78,500
+60% +$87.9K ﹤0.01% 5763
2025
Q2
$101K Buy
130,198
+21,100
+19% +$11.2K ﹤0.01% 5816
2025
Q1
$60K Buy
109,098
+7,700
+8% +$5.63K ﹤0.01% 5866
2024
Q4
$92.7K Buy
101,398
+16,400
+19% +$17.1K ﹤0.01% 5777
2024
Q3
$74K Buy
84,998
+1,400
+2% +$1.38K ﹤0.01% 5602
2024
Q2
$82.8K Hold
83,598
– – ﹤0.01% 5420
2024
Q1
$88.6K Buy
+83,598
New +$93.4K ﹤0.01% 5259
2021
Q2
– Sell
-10,300
Closed -$39K – 6416
2021
Q1
$39K Buy
+10,300
New +$30.7K ﹤0.01% 5967

Other funds holding ONCY

Goldman Sachs's ONCY Position: Q3 2026 in Review

Goldman Sachs increased its Oncolytics Biotech (ONCY) stake by 9.9% in Q3 2026, buying an estimated $13.6K and bringing the position to 186,639 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #6309.

Goldman Sachs first reported a position in ONCY in Q1 2021 and has held it in 11 quarters since. The position peaked at $292K in Q3 2025. 77 funds tracked by Wall St. Rank hold ONCY as of Q3 2026.

  • Goldman Sachs held 186,639 shares of Oncolytics Biotech worth $125K as of Q3 2026.
  • Goldman Sachs bought 16,741 Oncolytics Biotech shares in Q3 2026, an estimated $13.6K.
  • Oncolytics Biotech made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #6309 holding.
  • Goldman Sachs first reported a position in Oncolytics Biotech in Q1 2021 and has held it in 11 quarters since.
  • Goldman Sachs's Oncolytics Biotech position peaked at $292K in Q3 2025.
  • 77 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2026.

Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.